Cite
HARVARD Citation
Zhao, J. et al. (2022). Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal of clinical oncology. 40 (4), pp. 392-402. [Online].